297,328 Shares in AbbVie Inc. $ABBV Purchased by EP Wealth Advisors LLC

Key Points

• EP Wealth Advisors purchased 297,328 AbbVie shares in the second quarter, valued at approximately $74.8 million. Institutional investors and hedge funds collectively own 70.23% of the company.
• AbbVie reported better-than-expected quarterly results, with EPS of $3.65 and revenue of $16.99 billion, representing 10.2% year-over-year growth. The company issued third-quarter 2026 EPS guidance of $3.84–$3.88.
• Analysts maintain a generally positive view, with AbbVie carrying a “Moderate Buy” consensus rating and an average price target of $275.95. Shares opened at $259.87, while EVP Nicholas Donoghoe sold $8.18 million worth of stock.

EP Wealth Advisors LLC bought a new position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 297,328 shares of the company's stock, valued at approximately $74,820,000.

Several other hedge funds have also recently modified their holdings of ABBV. Norges Bank purchased a new position in shares of AbbVie in the fourth quarter valued at approximately $5,865,055,000. Wellington Management Group LLP boosted its position in shares of AbbVie by 457.4% during the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company's stock valued at $2,439,714,000 after acquiring an additional 8,646,424 shares during the last quarter. Capital World Investors grew its stake in shares of AbbVie by 106.3% in the 4th quarter. Capital World Investors now owns 13,071,444 shares of the company's stock valued at $2,986,777,000 after buying an additional 6,736,161 shares during the period. Cardano Risk Management B.V. lifted its holdings in AbbVie by 914.6% in the fourth quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company's stock valued at $1,244,112,000 after acquiring an additional 4,908,260 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of AbbVie by 10.4% during the 4th quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company's stock worth $10,179,099,000 after purchasing an additional 4,190,487 shares during the period. Institutional investors and hedge funds own 70.23% of the company's stock.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares of the company's stock, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.06% of the company's stock.

AbbVie Stock Up 1.3%

ABBV opened at $259.87 on Wednesday. The business has a 50 day moving average price of $253.69 and a two-hundred day moving average price of $229.43. The company has a market cap of $459.14 billion, a PE ratio of 73.41, a P/E/G ratio of 1.16 and a beta of 0.29. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $267.47.

AbbVie (NYSE:ABBV - Get Free Report) last released its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion during the quarter, compared to analysts' expectations of $16.80 billion. During the same quarter last year, the business earned $2.97 EPS. The business's revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts expect that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were given a dividend of $1.73 per share. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.7%. AbbVie's payout ratio is presently 195.48%.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Allergan Aesthetics, an AbbVie company, launched SkinMedica Barrier Calming Cream and introduced HA 5 Hydra Collagen Facial Mist. Clinical testing reportedly showed a 30% reduction in skin dryness after two weeks, supporting AbbVie’s aesthetics and consumer-health growth strategy. SkinMedica Adds Barrier Calming Cream
• Positive Sentiment: AbbVie is cited as a potential beneficiary of an aging population, with its immunology portfolio positioned to capture long-term healthcare demand. Aging Population Drives Healthcare Growth
• Neutral Sentiment: AbbVie will present at the Wells Fargo Healthcare Conference on September 9. The event could provide updates on its pipeline, Humira replacement products and financial outlook, but no new information was announced yet. AbbVie Wells Fargo Healthcare Conference
• Neutral Sentiment: Investors are largely waiting for AbbVie’s next earnings update, leaving the stock without a major new near-term catalyst. AbbVie Stock Holds Steady
• Neutral Sentiment: New 340B-related court developments could affect drug-company pricing and reimbursement, but the article does not identify a specific immediate impact on AbbVie. 340B Court Updates
• Negative Sentiment: Erste Group Bank reduced its fiscal 2026 EPS estimate for AbbVie, signaling somewhat more cautious expectations for earnings growth. AbbVie FY2026 EPS Estimates Reduced

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Canaccord Genuity Group lifted their target price on shares of AbbVie from $282.00 to $290.00 and gave the company a "buy" rating in a report on Monday, August 3rd. BNP Paribas Exane raised their target price on shares of AbbVie from $218.00 to $247.00 and gave the company a "neutral" rating in a report on Tuesday, August 11th. Bank of America raised their price objective on shares of AbbVie from $234.00 to $276.00 and gave the company a "buy" rating in a report on Friday, July 10th. HSBC reaffirmed a "buy" rating and set a $300.00 price objective on shares of AbbVie in a research report on Monday, July 6th. Finally, Erste Group Bank upgraded shares of AbbVie from a "hold" rating to a "buy" rating in a research note on Wednesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, AbbVie currently has a consensus rating of "Moderate Buy" and a consensus target price of $275.95.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source